U.S., March 14 -- ClinicalTrials.gov registry received information related to the study (NCT07469891) titled 'A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms' on Feb. 26.
Brief Summary: This is a first-in-human, open-label, multi-center Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and myelofibrosis (MF), and to determine the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE[s]). The study consists of a dose-escalation phase followed by a dose-expansion phase to further evaluate selected dose level(s).
Study Start Date: April, 2026
Study Type: INTERVENTIONAL...